166 related articles for article (PubMed ID: 22126913)
21. Abnormal metabolic brain network associated with Parkinson's disease: replication on a new European sample.
Tomše P; Jensterle L; Grmek M; Zaletel K; Pirtošek Z; Dhawan V; Peng S; Eidelberg D; Ma Y; Trošt M
Neuroradiology; 2017 May; 59(5):507-515. PubMed ID: 28386687
[TBL] [Abstract][Full Text] [Related]
22. Dopamine replacement therapy does not restore the full spectrum of normal pallidal activity in the 1-methyl-4-phenyl-1,2,3,6-tetra-hydropyridine primate model of Parkinsonism.
Heimer G; Rivlin-Etzion M; Bar-Gad I; Goldberg JA; Haber SN; Bergman H
J Neurosci; 2006 Aug; 26(31):8101-14. PubMed ID: 16885224
[TBL] [Abstract][Full Text] [Related]
23. Tremor is associated with PET measures of nigrostriatal dopamine function in MPTP-lesioned monkeys.
Eberling JL; Pivirotto P; Bringas J; Bankiewicz KS
Exp Neurol; 2000 Oct; 165(2):342-6. PubMed ID: 10993693
[TBL] [Abstract][Full Text] [Related]
24. Convection-enhanced selective excitotoxic ablation of the neurons of the globus pallidus internus for treatment of parkinsonism in nonhuman primates.
Lonser RR; Corthésy ME; Morrison PF; Gogate N; Oldfield EH
J Neurosurg; 1999 Aug; 91(2):294-302. PubMed ID: 10433318
[TBL] [Abstract][Full Text] [Related]
25. Intraputamenal infusion of exogenous neurturin protein restores motor and dopaminergic function in the globus pallidus of MPTP-lesioned rhesus monkeys.
Grondin R; Zhang Z; Ai Y; Ding F; Walton AA; Surgener SP; Gerhardt GA; Gash DM
Cell Transplant; 2008; 17(4):373-81. PubMed ID: 18522240
[TBL] [Abstract][Full Text] [Related]
26. Serotonergic innervation of the striatum in a nonhuman primate model of Parkinson's disease.
Jiménez-Sánchez L; Blesa J; Del Rey NL; Monje MHG; Obeso JA; Cavada C
Neuropharmacology; 2020 Jun; 170():107806. PubMed ID: 31589886
[TBL] [Abstract][Full Text] [Related]
27. Progression of dopaminergic depletion in a model of MPTP-induced Parkinsonism in non-human primates. An (18)F-DOPA and (11)C-DTBZ PET study.
Blesa J; Juri C; Collantes M; Peñuelas I; Prieto E; Iglesias E; Martí-Climent J; Arbizu J; Zubieta JL; Rodríguez-Oroz MC; García-García D; Richter JA; Cavada C; Obeso JA
Neurobiol Dis; 2010 Jun; 38(3):456-63. PubMed ID: 20304066
[TBL] [Abstract][Full Text] [Related]
28. SPECT imaging, immunohistochemical and behavioural correlations in the primate models of Parkinson's disease.
Ashkan K; Wallace BA; Mitrofanis J; Pollo C; Brard PY; Fagret D; Benabid AL
Parkinsonism Relat Disord; 2007 Jul; 13(5):266-75. PubMed ID: 17196871
[TBL] [Abstract][Full Text] [Related]
29. Endogenous morphine-like compound immunoreactivity increases in parkinsonism.
Charron G; Doudnikoff E; Laux A; Berthet A; Porras G; Canron MH; Barroso-Chinea P; Li Q; Qin C; Nosten-Bertrand M; Giros B; Delalande F; Van Dorsselaer A; Vital A; Goumon Y; Bezard E
Brain; 2011 Aug; 134(Pt 8):2321-38. PubMed ID: 21742735
[TBL] [Abstract][Full Text] [Related]
30. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
Pope-Coleman A; Tinker JP; Schneider JS
Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
[TBL] [Abstract][Full Text] [Related]
31. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model.
Brownell AL; Canales K; Chen YI; Jenkins BG; Owen C; Livni E; Yu M; Cicchetti F; Sanchez-Pernaute R; Isacson O
Neuroimage; 2003 Oct; 20(2):1064-75. PubMed ID: 14568476
[TBL] [Abstract][Full Text] [Related]
32. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
33. Parkinson's disease tremor-related metabolic network: characterization, progression, and treatment effects.
Mure H; Hirano S; Tang CC; Isaias IU; Antonini A; Ma Y; Dhawan V; Eidelberg D
Neuroimage; 2011 Jan; 54(2):1244-53. PubMed ID: 20851193
[TBL] [Abstract][Full Text] [Related]
34. Metabolic network expression in parkinsonism: Clinical and dopaminergic correlations.
Ko JH; Lee CS; Eidelberg D
J Cereb Blood Flow Metab; 2017 Feb; 37(2):683-693. PubMed ID: 26980757
[TBL] [Abstract][Full Text] [Related]
35. Vector-mediated l-3,4-dihydroxyphenylalanine delivery reverses motor impairments in a primate model of Parkinson's disease.
Rosenblad C; Li Q; Pioli EY; Dovero S; Antunes AS; Agúndez L; Bardelli M; Linden RM; Henckaerts E; Björklund A; Bezard E; Björklund T
Brain; 2019 Aug; 142(8):2402-2416. PubMed ID: 31243443
[TBL] [Abstract][Full Text] [Related]
36. Dopamine turnover is upregulated in the caudate/putamen of asymptomatic MPTP-treated rhesus monkeys.
Pifl C; Hornykiewicz O
Neurochem Int; 2006 Oct; 49(5):519-24. PubMed ID: 16698121
[TBL] [Abstract][Full Text] [Related]
37. Evidence of oligodendrogliosis in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced Parkinsonism.
Annese V; Barcia C; Ros-Bernal F; Gómez A; Ros CM; De Pablos V; Fernández-Villalba E; De Stefano ME; Herrero MT
Neuropathol Appl Neurobiol; 2013 Feb; 39(2):132-43. PubMed ID: 22443457
[TBL] [Abstract][Full Text] [Related]
38. Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET.
Ma Y; Johnston TH; Peng S; Zuo C; Koprich JB; Fox SH; Guan Y; Eidelberg D; Brotchie JM
Mov Disord; 2015 Aug; 30(9):1283-8. PubMed ID: 26377152
[TBL] [Abstract][Full Text] [Related]
39. Reduced noradrenaline, but not dopamine and serotonin in motor thalamus of the MPTP primate: relation to severity of parkinsonism.
Pifl C; Hornykiewicz O; Blesa J; Adánez R; Cavada C; Obeso JA
J Neurochem; 2013 Jun; 125(5):657-62. PubMed ID: 23331162
[TBL] [Abstract][Full Text] [Related]
40. 99mTc-TRODAT-1 SPECT in healthy and 6-OHDA lesioned parkinsonian monkeys: comparison with 18F-FDOPA PET.
Huang WS; Ma KH; Chou YH; Chen CY; Liu RS; Liu JC
Nucl Med Commun; 2003 Jan; 24(1):77-83. PubMed ID: 12501023
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
